Grimes & Company Inc. Sells 16,702 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Grimes & Company Inc. reduced its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 41.8% in the third quarter, Holdings Channel.com reports. The fund owned 23,285 shares of the biotechnology company’s stock after selling 16,702 shares during the quarter. Grimes & Company Inc.’s holdings in ADMA Biologics were worth $465,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. D. E. Shaw & Co. Inc. lifted its stake in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of ADMA Biologics by 1.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock worth $37,813,000 after acquiring an additional 35,707 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in shares of ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after acquiring an additional 447,743 shares during the last quarter. Mesirow Institutional Investment Management Inc. bought a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $17,221,000. Finally, Renaissance Technologies LLC increased its holdings in ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after purchasing an additional 575,100 shares during the period. 75.68% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Trading Up 1.7 %

Shares of NASDAQ:ADMA opened at $15.96 on Friday. ADMA Biologics, Inc. has a 12-month low of $3.13 and a 12-month high of $21.13. The business’s fifty day simple moving average is $17.97 and its 200-day simple moving average is $12.91. The company has a market capitalization of $3.70 billion, a PE ratio of -798.00 and a beta of 0.62. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same period last year, the business posted ($0.02) EPS. The business’s revenue was up 78.4% compared to the same quarter last year. As a group, equities research analysts predict that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADMA has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of ADMA Biologics in a report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.